Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors. The new funding will be used to accelerate the company's growth and support the launch of two new commercial products, O-Predict and O-Validate for oncology drug development. Founded […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!